Sirana Pharma develops microRNA (miRNA)-targeting approaches to treat aging-related and hereditary musculoskeletal diseases. This includes osteoporosis (fragile bones), sarcopenia (muscle weakness) and osteogenesis imperfecta (brittle bones). These conditions demand new and better treatments. Thus, Sirana Pharma has developed novel miRNA-based targeted modalities to treat these conditions that stimulate the formation of new bone while attenuating a pathologically elevated bone resorption. In addition, the intervention improves muscle strength and fatigue under various disease conditions, which makes it unique. Sirana Pharma received seed funding from the High-Tech Gründerfonds (HTGF), recently closed a research collaboration with Pfizer and is currently preparing a funding round with a syndicate of experienced investors.